Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Titel:
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Auteur:
Rosell, Rafael Carcereny, Enric Gervais, Radj Vergnenegre, Alain Massuti, Bartomeu Felip, Enriqueta Palmero, Ramon Garcia-Gomez, Ramon Pallares, Cinta Sanchez, Jose Miguel Porta, Rut Cobo, Manuel Garrido, Pilar Longo, Flavia Moran, Teresa Insa, Amelia De Marinis, Filippo Corre, Romain Bover, Isabel Illiano, Alfonso Dansin, Eric de Castro, Javier Milella, Michele Reguart, Noemi Altavilla, Giuseppe Jimenez, Ulpiano Provencio, Mariano Moreno, Miguel Angel Terrasa, Josefa Muñoz-Langa, Jose Valdivia, Javier Isla, Dolores Domine, Manuel Molinier, Olivier Mazieres, Julien Baize, Nathalie Garcia-Campelo, Rosario Robinet, Gilles Rodriguez-Abreu, Delvys Lopez-Vivanco, Guillermo Gebbia, Vittorio Ferrera-Delgado, Lioba Bombaron, Pierre Bernabe, Reyes Bearz, Alessandra Artal, Angel Cortesi, Enrico Rolfo, Christian Sanchez-Ronco, Maria Drozdowskyj, Ana Queralt, Cristina de Aguirre, Itziar Ramirez, Jose Luis Sanchez, Jose Javier Molina, Miguel Angel Taron, Miquel Paz-Ares, Luis